141 related articles for article (PubMed ID: 36590753)
21. A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than risk of ovarian malignancy algorithm (ROMA) in ovarian carcinoma.
Zhu C; Zhang N; Zhong A; Xiao K; Lu R; Guo L
Clin Chim Acta; 2022 Jan; 524():43-50. PubMed ID: 34813778
[TBL] [Abstract][Full Text] [Related]
22. Low serum T3 levels are associated with false-positive results when using the risk of ovarian malignancy algorithm (ROMA) in women with benign ovarian disease.
Park H; Lee DW; Kim MJ; Shin JE; Lee HN
Taiwan J Obstet Gynecol; 2021 Jan; 60(1):36-40. PubMed ID: 33495005
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
[TBL] [Abstract][Full Text] [Related]
24. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
25. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
26. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.
Lu J; Zheng Z; Zhang Q; Li G; Li F; Le Z; Huang J; Xie X; Zhang J
J Clin Lab Anal; 2018 Jun; 32(5):e22368. PubMed ID: 29194801
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of HE4 and ROMA among Chinese women.
Shen Y; Zhao L; Lu S
Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
[TBL] [Abstract][Full Text] [Related]
28. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in Post-Menopausal Patients with Ovarian Mass.
Salim E; Zubairi AM; Danish SH; Ali U
J Coll Physicians Surg Pak; 2018 Jun; 28(6):440-444. PubMed ID: 29848419
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
33. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
[TBL] [Abstract][Full Text] [Related]
34. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma.
Modarres-Gilani M; Vaezi M; Shariat M; Zamani N; Nourizadeh R
Cancer Biomark; 2017 Aug; 20(2):135-141. PubMed ID: 28800309
[TBL] [Abstract][Full Text] [Related]
36. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
37. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
Ikeda Y; Hasegawa K; Kurosaki A; Miyara A; Hanaoka T; Shintani D; Imai Y; Nishikawa T; Oda K; Fujiwara K
Oncol Res Treat; 2015; 38(6):276-81. PubMed ID: 26045023
[TBL] [Abstract][Full Text] [Related]
38. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
40. Applying low coverage whole genome sequencing to detect malignant ovarian mass.
Chen M; Zhong P; Hong M; Tan J; Yu X; Huang H; Ouyang J; Lin X; Chen P
J Transl Med; 2021 Aug; 19(1):369. PubMed ID: 34446054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]